1	Overdose mortality rates for opioids or stimulants
2	are higher in males than females, controlling for rates of drug misuse:
3	State-level data
4	
5	
6	
7	
8	Eduardo R. Butelman Ph.D.', Yuefeng Huang Ph.D.', David H. Epstein Ph.D. ² , Yavin Shaham Ph.D. ² ,
9	Rita Z. Goldstein Ph.D.', Nora D. Volkow M.D.', Nelly Alia-Klein Ph.D.'
10	
11	Affiliations:
12	'Neuropsychoimaging of Addiction and Related Conditions Research Program,
13	Departments of Psychiatry and Neuroscience
14	Icahn School of Medicine at Mount Sinai, New York, NY
15	² National Institute on Drug Abuse (NIDA), Baltimore, MD
16	
17	
18 19 20 21 22 23 24 25 26 27 28 29 30 31	Corresponding Author: E.R. Butelman Ph.D. NARC Program Department of Psychiatry Icahn School of Medicine at Mount Sinai One Gustave L. Levy Place Box 1217 New York, NY 10029-6574 Email: <u>eduardo.butelman@mssm.edu</u> Phone: 212 241-6500
32 33 34 35	Word Count: 2983 Words

- 36
- 37 38
- 39

40 **Abbreviations:**

- 41 95%Cl: 95% confidence interval
- 42 CDC: Centers for Disease Control and Prevention
- 43 ICD-10: International Classification of Diseases, 10th Edition
- 44 Psychostimulants: Abbreviation for ICD-10 category T43.6; "psychostimulants with potential for misuse,
- 45 excluding cocaine"
- 46 SUD: Substance use disorders

48 Key Points:

- Question: What are the current national trends in overdose mortality from opioids (synthetic opioids such as
 fentanyl, and heroin) and stimulant drugs (psychostimulants such as methamphetamine and cocaine) for males
 and females, over the lifespan (overall range 15-74 years)?
- 53 **Findings:** State-level analyses of data from CDC for 2020-2021 indicate that after controlling for rates of drug
- 54 misuse, males had significantly greater (2-3 fold) overdose mortality rates than females for synthetic opioids,
- 55 heroin, psychostimulants and cocaine. These findings were generally consistent across the lifespan, studied as
- 56 10-year age bins (especially in the 25-64 age range).

57

Meaning: These data indicate that males who misuse opioids and stimulant drugs are considerably more
vulnerable to overdose mortality, compared to females. This finding calls for research on the underlying
biological, behavioral, and social factors.

61

62

64 Abstract

- 65 **Importance:** Drug overdoses from opioids like fentanyl and heroin and stimulant drugs such as
- 66 methamphetamine and cocaine are a major cause of mortality in the United States, with potential sex
- 67 differences across the lifespan.
- 68 **Objective:** To determine overdose mortality for specific drug categories across the lifespan of males and
- 69 females, using a nationally representative state-level sample.
- 70 **Design:** State-level analyses of nationally representative epidemiological data on overdose mortality for
- 51 specific drug categories, across 10-year age bins (age range: 15-74).
- 72 Setting: Population-based study of Multiple Cause of Death 2020-2021 data from the Centers of Disease
- 73 Control and Prevention (CDC WONDER platform).
- 74 Participants: Decedents in the United States in 2020-2021
- 75 Main outcome measures: The main outcome measure was sex-specific rates of overdose death (per
- 100,000) for: synthetic opioids excluding methadone (ICD-10 code: T40.4; predominantly fentanyl), heroin
- 77 (T40.1), psychostimulants with potential for misuse, excluding cocaine (T43.6, predominantly
- methamphetamine; labeled "psychostimulants" hereafter), and cocaine (T40.5). Multiple regression analyses
- 79 were used to control for ethnic-cultural background, household net worth, and sex-specific rate of misuse of the
- relevant substances (from the National Survey on Drug Use and Health, 2018-2019).
- 81 **Results:** For each of the drug categories assessed, males had greater overall overdose mortality than
- 82 females, after controlling for rates of drug misuse. The mean male/female sex ratio of mortality rate for the
- separate drug categories was relatively stable across jurisdictions: synthetic opioids (2.5 [95%Cl, 2.4-2.7]),
- heroin, (2.9 [95%Cl, 2.7-3.1], psychostimulants (2.4 [95%Cl, 2.3-2.5]), and cocaine (2.8 [95%Cl, 2.6-2.9]). With
- 85 data stratified in 10-year age bins, the sex difference generally survived adjustment for state-level ethnic-
- cultural and economic variables, and for sex-specific misuse of each drug type (especially for bins in the 25-64
- age range). For synthetic opioids, the sex difference survived adjustment across the lifespan (i.e., 10-year age
- bins ranging from 15-74), including adolescence, adulthood and late adulthood.

- 89 Conclusions and Relevance: The robustly greater overdose mortality in males versus females for synthetic
- 90 opioids (predominantly fentanyl), heroin, and stimulant drugs including methamphetamine and cocaine indicate
- 91 that males who misuse these drugs are significantly more vulnerable to overdose deaths. These results call for
- 92 research into diverse biological, behavioral, and social factors that underlie sex differences in human
- 93 vulnerability to drug overdose.
- 94

95 Introduction

Overdose deaths due to opioids (such as fentanyl and heroin), or stimulant drugs (such as
 methamphetamine and cocaine) have increased in recent years in the United States.¹⁻³ This increase has
 accelerated since the onset of the COVID-19 pandemic (March 2020 and thereafter) for fentanyl and its
 analogs and stimulants such as methamphetamine, but not for heroin, prescription opioids, or methadone.⁴⁻⁷
 This was due in part to increases in the distribution of synthetic opioids such as fentanyl, and their use to lace
 other drugs, including illicitly manufactured preparations disguised as prescription opioid analgesics, stimulant
 medications or benzodiazepines.^{6, 8, 9}

Prevention of overdose death requires the identification of vulnerability factors, which are thought to 103 include sex and age.⁶ Regarding sex as a biological variable, results from studies using rodent models are 104 inconclusive due to conflicting results: some such studies have shown that female rats are more prone to 105 escalate their intake of opioids or stimulant drugs,¹⁰ but a large number of other studies have not.¹¹ Similarly, 106 some studies in human cohorts have shown that females escalated their intake of opioids or stimulant drugs 107 more rapidly than males,¹²⁻¹⁵ but several other studies have not.¹⁶⁻¹⁸ A recent comprehensive review did not 108 find robust sex differences in vulnerability to craving and relapse.¹¹ Nonetheless, as reviewed below, 109 epidemiological data have suggested a sex difference in risk of overdose death, and those findings need to be 110 followed up on. 111

Regarding age, epidemiological studies have suggested typical trajectories in which misuse of opioids or stimulant drugs begins in late adolescence or young adulthood and escalates thereafter.^{18, 19} However, the onset of misuse may also occur later in the lifespan, sometimes triggered iatrogenically.^{20, 21} Relatively recent data also point to an increase in older adults (aged 55 and older) seeking first-time treatment for OUD.²²

Epidemiological studies show that males, compared to females, tend to have greater overdose mortality. For example, a recent report for 2019-2020, for 25 states and the District of Columbia, showed an increase in overdose mortality for all drugs combined, with a greater rate in males versus females.²³ Similarly,

a US nation-level analysis of mortality data showed an increase in overdoses from synthetic opioids (thus
 including fentanyl but not heroin) and psychostimulants (including methamphetamine but not cocaine) from
 March 2018 to March 2021, with highest mortality rates in males (especially from minoritized groups, e.g.,
 African-American).⁴ A nation-level report on CDC data from 2017-2018 showed that males compared to
 females had greater overdose mortality for prescription opioids specifically, and for all opioids combined.⁶

In the analyses reported here, we followed up on those findings in greater depth, focusing on the sex 124 difference across the lifespan, and asking whether its magnitude is consistent across US jurisdictions (50 125 states and district of Columbia), which can differ in major demographic and socioeconomic variables, levels of 126 misuse, and illicit drug market factors.²⁴ We examined overdose mortality separately for specific categories of 127 opioid and stimulant drugs, due to their differing mechanisms of toxicity.²⁵ Acute overdose mortality from 128 opioids (mu-opioid receptor agonists) is primarily attributed to respiratory depression mediated by brainstem 129 nuclei.^{26, 27} Overdose mortality from fentanyl and its analogs may be greater than that for heroin, due to 130 greater potency, faster onset of action driven by high lipophilicity, and higher likelihood to trigger chest 131 rigidity.²⁸⁻³⁰ It is not clear whether there are generalizable sex differences in sensitivity to respiratory 132 depressant effects of mu-opioid agonists in humans.³¹⁻³⁴ Epidemiological data do not directly address this 133 guestion, but could provide evidence against it (or in favor of additional explanations) if the sex difference in 134 overdose mortality is not consistent across state-level jurisdictions. 135

Acute overdose mortality by methamphetamine and cocaine in humans is primarily attributed to cardiovascular and neurological events such as malignant arrhythmias, strokes, or seizures.^{35, 36} Some, but not all, human studies reported that females had either more prolonged or more pronounced cardiovascular effects than males after administration of stimulant drugs.³⁷⁻⁴⁰ Again, epidemiological data cannot directly address questions of biological vulnerability, but could constrain hypotheses, depending on whether the sex difference in overdose mortality is consistent across states that differ in major demographic, socioeconomic and drug use factors.

In addition to sex differences in direct pathophysiological effects of the drug, factors that could account 143 for stable variations in rates of overdose include: family and social interactions and related trauma.^{41, 42} 144 propensity toward risky behaviors (e.g., injecting alone, taking large doses, or using untrusted suppliers).^{43, 44} 145 and propensity to seek treatment.⁴⁵⁻⁴⁹ We expect that differences in these gendered behavioral factors would 146 147 be largely consistent across drug categories and states in the US. Other contributing factors which could differ by state within the US include ethnic-cultural background, socioeconomic variables, illicit drug supply, and 148 availability of evidence-based care.^{8, 50-53} Using state-level nationally representative CDC data for 2020-2021, 149 the goal of this study was therefore to determine the extent to which sex differences in overdose mortality vary 150 in four mutually exclusive drug categories (synthetic opioids, heroin, psychostimulants such as 151 methamphetamine, and cocaine) and state, accounting for age. Different patterns of sex variability in overdose 152 mortality would suggest (without proving or ruling out) different emphases on possible levels of causation. 153

154 Methods

This was a study of de-identified publicly available data from the CDC "multiple cause mortality" data, obtained from the CDC WONDER platform for the years 2020-2021 (https://wonder.cdc.gov/mcd.html), which provides information based on death certificates in the United States. Overdose mortality data that were "suppressed" (due to n<10 per cell) or deemed "unreliable" in CDC WONDER were considered missing and were excluded from analysis. Data were analyzed in October 2022-February 2023. This study followed reporting guidelines from: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).

161

Data set: The main analyzed outcome variable was crude death rate per 100,000 population for Drug Poisonings (ICD-10 codes for overdoses; including unintentional X40-X44, suicide X60-X64, homicide X85, and undetermined intents Y10-Y14). Data were obtained for four mutually exclusive categories: synthetic opioids other than methadone ("synthetic opioids" hereafter; this predominantly reflects fentanyl and its analogs, but also compounds from other chemical scaffolds; T40.4),⁵⁴ heroin (T40.1), psychostimulants with

potential for misuse (which predominantly reflects methamphetamine; T43.6) and for cocaine (T40.5). Data
 were stratified by sex and by six consecutive 10-year age bins (i.e., 15-24, 25-34, 35-44, 45-54, 55-64 and 65 obtained for 51 jurisdictions (50 states and the District of Columbia) for 2020-2021.⁵⁵

170

Nomenclature: This manuscript will use the terms "male" and "female" for data analyses ⁵⁶, as this is the terminology used in death certificates, the root document for mortality data in CDC WONDER. For clarity, we use the term *"stimulant drugs"* to encompass compounds such as methamphetamine and cocaine overall, and use the term "psychostimulants" for the CDC overdose category (T43.6) that predominantly reflects methamphetamine. As stated above, cocaine overdoses (T40.5) are analyzed in a separate category from psychostimulants.

177

Data Analyses: All analyses were carried out with GraphPad Prism V.9, using jurisdiction-level data.

179 Univariate analyses included Spearman correlations on overdose mortality data (crude death rate per 100,000

180 population) for males and females, per jurisdiction. Mortality and misuse ratios in males/females were

181 compared with Wilcoxon tests. Univariate mixed-effects ANOVAs (sex x age bin) then analyzed log-

transformed overdose mortality rate across the lifespan, stratified in six consecutive 10-year age bins;

significant effects were followed with post-hoc Bonferroni tests.

Separately for each drug category (all ages combined in the range 15-74 years), multivariable analyses were then carried out with multiple linear (least squares) regressions, to assess the effect of sex and selected potential covariates on the outcome, log-transformed death rates. Thus, the independent variables included: sex (M/F), percent of the population who is white, percent of the population who is black (from the 5-year American Community Survey for 2020 from the U.S. Census Bureau;

189 <u>https://worldpopulationreview.com/states/states-by-race</u>), and median household net worth in 2020

190 (www.census.gov/data/tables/2020/demo/wealth/state-wealth-asset-ownership.html). Using data from the

National Survey on Drug Use and Health (NSDUH) for 2018-2019, we also controlled for overall levels of 191 192 misuse of the relevant drugs (https://rdas.samhsa.gov/#/survey/NSDUH-2018-2019-RD02YR). Thus, the multiple linear regressions for overdose mortality by synthetic opioids and heroin controlled for the rate of past-193 year misuse of opioids, by sex (item "OPINMYR" in the NSDUH survey). Likewise, the regressions for 194 195 overdose mortality caused by psychostimulants or cocaine controlled for the rate of past-year misuse of these drugs, by sex (items "AMMEPDPYMU" and "COCMYR" in the NSDUH survey, respectively). Using the NSDUH 196 survey, we were not able to perform state- and sex-specific analyses of relevant substance use disorders (as 197 opposed to misuse), because of frequent data suppression after stratification. The overdose mortality data 198 were also stratified by 10-year age bins (overall range: 15-74 years), and multiple regressions were run 199 separately for each age bin. 200

In the ANOVAs and multiple regressions, outliers for the outcome variable (greater than ± 1.96 standard deviations from the mean were removed, using Grubbs test at the 5% alpha level of significance. Also, if there were <10 jurisdictions in which overdose mortality data were not available for both males and females for an age bin and drug category, the data set was excluded from analysis, in order to maintain representativeness. The overall alpha level of significance was set at the p=0.05 level, two-tailed.

206 In a supplementary analysis, we also examined analogously overdoses caused by both synthetic 207 opioids *and* psychostimulants (a common poly-drug pattern of overdose) (Supplement).^{3, 57}

208 **Results**:

Overall overdose mortality profiles (all ages combined): With all ages combined (overall range 15-74 years), there was a broad range of overdose mortality rates for the four drug categories, across jurisdictions (Figures 1 and 2; lower panels, and eTable 1). There were positive Spearman correlations, nearing unity, in the rate of overdose mortality for males and females in the same jurisdiction, for each of the drug categories (Spearman correlations ranged from +0.94 to +0.97; all p-values were <0.0001) (see lower panels of Figure 1 for synthetic opioids and heroin, and Figure 2 for psychostimulants and cocaine). Simple linear regressions

215	provided a strong fit for these data (R ² values of 0.95, 0.88, 0.92 and 0.95, for synthetic opioids, heroin,
216	psychostimulants and cocaine respectively). The mean ratios for mortality in males/females (all ages
217	combined) were in the 2.4-2.9 range: ratios were 2.5 (95%CI: 2.4-2.7) for synthetic opioids, 2.9 (95%CI: 2.7-
218	3.1) for heroin, 2.4 (95%CI: 2.3-2.5) for psychostimulants and 2.8 (95%CI: 2.6-2.9) for cocaine.

In contrast, the correlations for past-year drug misuse between males and females within jurisdictions were of smaller magnitude, ranging from Spearman r value of 0.29 for opioids, to 0.60 for psychostimulants, and 0.66 for cocaine) (Figures 1 and 2; upper panels). Also, the male/female ratios of misuse were significantly smaller than the male/female ratios for overdose mortality, for each of these drug categories (see Figure 3).

223 Univariate analyses of overdose mortality across the lifespan: Separate 2x2 ANOVAs (sex x age 224 bin) were carried out for each drug category. For synthetic opioids, psychostimulants and cocaine, there were 225 significant main effects of sex and age bin, and also a sex by age bin interaction (see Figure 4 and eTables 2 226 and 3). For heroin, there were significant main effects of sex and age bin, but the interaction did not reach 227 significance. Post-hoc Bonferroni tests for sex at each age bin showed that with few exceptions (typically for 228 the youngest and oldest age bins, where the lowest rates were observed), males had greater mortality than 229 females.

Multivariable analyses: Multiple linear regressions were conducted for each drug category separately, with all ages combined (age range 15-74). Sex remained a significant factor for overdose mortality for all drug categories, after adjustment for the jurisdiction-level sex-specific rate of misuse of the relevant drugs, and for demographic variables (distribution of major ethnic-cultural groups and median household net worth) (see eTable 4, and Figure 5).

235 Similar multiple linear regressions were then conducted, after stratification into 10-year age bins. For all 236 drug categories and age bins, sex remained a significant factor in overdose mortality rates after adjustment. Of 237 note, that included the 55-64 age bin (see eTable 5 and Figure 5).

238 Supplementary analysis of overdose mortality caused by both synthetic opioids and

psychostimulants: In a follow-up analysis, we examined overdose mortality caused by a commonly reported
 pattern of polydrug use: combining synthetic opioids and psychostimulants (i.e., ICD-10 codes T40.4 and
 T43.6 reported together as multiple causes of mortality).^{3, 57, 58} This outcome generally followed a similar profile
 across the lifespan, with males having greater mortality rates than females (eFigure 1, eTable 6 and eTable 7).

243

244 Discussion

This was a nationally representative state- and age- specific examination of differences between males and females in overdose mortality due to opioid and stimulant drugs, for 2020-2021. The study showed that for these drug categories, across the lifespan, after controlling for sex-specific levels of past-year drug misuse and for major demographic factors, males died from overdoses at an approximately 2-3 greater rate than females. Studies from several other industrialized countries do show greater drug-induced mortality for males versus females ^{59, 60}. However, to the best of our knowledge, recent comparative data for these different drugs, stratified by age, are not published for a broad set of countries.

For synthetic opioids, the effect of sex on overdose mortality survived adjustment in all 10-year age bins (overall range 15-74 years). For the other drug categories under study (heroin, psychostimulants and cocaine), this effect of sex survived adjustment in age bins in the 25-64 age range. Therefore, for all the drugs studied here, greater overdose mortality rates were observed in males versus females in the 55-64 age bin, considered to be in the post-menopausal range for the population. ⁶¹

The robustness of the overall sex difference in overdose mortality, even after controlling for different propensity to misuse, and across state-level jurisdictions, shows that males in the US are reliably at greater risk of fatal overdose than females. Mechanistic explanations cannot be directly derived from these epidemiological data, but some processes can be accorded greater likelihood of accounting for most of the sex difference. Sex-specific biological vulnerability to the direct toxic effects of the drugs, for example, cannot be

ruled out. However, this sex-specific vulnerability would have to be shared across mu-opioid agonists and stimulant drugs, whose toxic effects are highly distinct from each other, in terms of pharmacodynamic targets and pathophysiological mechanisms. Even within these major drug categories, the pharmacodynamics and pathophysiological effects of specific mu-opioid agonists such as fentanyl versus morphine derivatives such as heroin,^{29, 30} and methamphetamine versus cocaine,^{62, 63} are not identical.

There are sex differences in the propensity to development of substance-use disorders (SUDs), but they appear unlikely to account for the observed difference in mortality rates. Nation-level data from the 2021 NSDUH⁶⁴ show that the overall male/female ratio in prevalence of any past-year SUD (all drugs combined) was 1.3 (9.8% of males versus 7.4% of females)—a considerably smaller sex difference than the one we observed in mortality rates. We noted earlier than other, more culture-bound differences between men and women could include differential propensity toward risky behaviors, above and beyond any risk inherent in misusing an opioid or stimulant—e.g., injecting alone,^{43, 44} taking large doses, or using untrusted suppliers.

To explore the possibility that such a broader difference in risky behaviors underlies mortality, we 274 275 undertook a follow-up analysis of the same CDC WONDER dataset for 2020-2021, for the broad category of "Transport Accidents" (ICD-10 codes: V01-V99, thus including decedent drivers, passengers and pedestrians). 276 Using state-level data, the male/female ratio in fatalities due to transport accidents is similar in magnitude and 277 consistency to the ratios observed above for overdose mortality (i.e., the mean male/female ratio for transport 278 279 accidents was 2.68; 95%CI: 2.60-2.76, with a correlation for males and females in the same jurisdiction nearing unity; Spearman r=0.97; p<0.0001). One caveat is that these CDC data on transport accidents 280 combine instances in which the decedent was or was not determined to be responsible for the event. A 281 published study, however, suggests that men are 2-3 fold more likely than women to be responsible for motor 282 collisions, and are not more likely to be passive victims of motor collisions.⁶⁵ This is consistent with recent 283 nationally representative US data sets (e.g., from 2020) showing that male drivers who died as a result of 284 traffic accidents had a greater likelihood of engaging in risky behaviors such as speeding, compared to female 285 drivers ⁶⁶. We suspect that this type of sex difference is a valuable starting point for the exploration of both a 286

major mechanism and a modifiable risk factor in overdose deaths, but this explanation does not exclude important roles for other biological, behavioral or social factors.

Limitations: We focused on drug categories that greatly contribute to overdose deaths in the US at this time^{3, 4, 67}, but there is a need for similar examination of sex differences in overdose death from prescription opioids, benzodiazepines and alcohol.^{6, 68} Also, we cannot fully exclude the possibility that some of the sex differences in overdose mortality or misuse are due to reporting biases.^{69, 70} In addition, state- and sex- level data on drug misuse from NSDUH for years after 2019 are not are not currently publicly available. Also, it should be noted that the opioid misuse data in NSDUH (item OPINMYR) can encompass other compounds, in addition to synthetic opioids and heroin.

Conclusions: We performed a state-level analysis of recent nationally representative data, and found that 296 males, compared to females, have a significantly greater rate of overdose mortality from synthetic opioids, 297 298 heroin, and stimulant drugs such as methamphetamine and cocaine. An important finding in our study is that greater mortality in males was evident even after controlling for levels of misuse. These sex differences were 299 observed across the lifespan (e.g., in the range of 25-64 years of age), and were stable across states that have 300 broad range of environmental variables. Overall, these findings underscore that sex differences are important 301 targets for investigation at multiple biological and behavioral levels, potentially leading to optimized prevention 302 and intervention approaches to mitigate the risk of overdose mortality, at different stages across the lifespan. 303

- 304 **Author Contributions:** All authors contributed to the writing and editing process, including text and data
- analysis quality, and approved submission of the manuscript. All authors agree to be accountable for all
- aspects of the manuscript, including accuracy and integrity, and investigation and resolution of any potential
- 307 discrepancies.
- 308 Data Availability Statement: This study used publicly available de-identified information, data sources are
- 309 described in the Methods section.
- Funding: This work was supported by NIDA U01DA053625 (ERB), NIDA 1RO1DA048301-01A1 (RZG) and
- 311 NIDA 1RO1DA049547 (NAK), and by Intramural Research Program funds of NIDA (YS and DHE).
- 312 **Competing Interests:** The authors have nothing to disclose.
- 313
- 314

315 References

Brown KG, Chen CY, Dong D, Lake KJ, Butelman ER. Has the United States Reached a Plateau in
Overdoses Caused by Synthetic Opioids After the Onset of the COVID-19 Pandemic? Examination of Centers
for Disease Control and Prevention Data to November 2021. *Frontiers in psychiatry*.
2022: https://www.frontiersin.org/orticles/10.3289/fpsyt.2022.047603/full

320 2022;https://www.frontiersin.org/articles/10.3389/fpsyt.2022.947603/full

321

2. Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 2013–2019. *MMWR Morbidity and mortality weekly report*. 2021;70:202-207. doi:http://dx.doi.org/10.15585/mmwr.mm7006a4

325

326 3. Kariisa M, Seth P, Scholl L, Wilson N, Davis NL. Trends in drug overdose deaths involving cocaine and 327 psychostimulants with abuse potential among racial and ethnic groups – United States, 2004–2019. *Drug Alc* 328 *Depend*. 2021/08/28/ 2021:109001. doi:https://doi.org/10.1016/j.drugalcdep.2021.109001

329

Han B, Einstein EB, Jones CM, Cotto J, Compton WM, Volkow ND. Racial and Ethnic Disparities in
 Drug Overdose Deaths in the US During the COVID-19 Pandemic. *JAMA Netw Open*. Sep 1
 2022;5(9):e2232314. doi:10.1001/jamanetworkopen.2022.32314

333

5. Glicksberg L, Dempsey SK, Casey BK. Heroin and fentanyl in Dallas County: A 5-year retrospective review of toxicological, seized drug, and demographical data. *J Forensic Sci*. Oct 27 2022;DOI: 10.1111/1556-4029.15155doi:10.1111/1556-4029.15155

337

Wilson N, Kariisa M, Seth P, Smith Ht, Davis NL. Drug and Opioid-Involved Overdose Deaths - United
States, 2017-2018. *MMWR Morbidity and mortality weekly report*. Mar 20 2020;69(11):290-297.
doi:10.15585/mmwr.mm6911a4

341

Krawczyk N, Rivera BD, Basaraba C, et al. COVID-19 complications among patients with opioid use
 disorder: a retrospective cohort study across five major NYC hospital systems. *Addiction (Abingdon, England)*.
 Dec 2 2022;doi:10.1111/add.16105

345

8. Kilmer B, Pardo B, Pujol TA, Caulkins JP. Rapid changes in illegally manufactured fentanyl products and prices in the United States. *Addiction (Abingdon, England)*. May 11 2022;DOI: 10.1111/add.15942

348 doi:10.1111/add.15942

349

Palamar JJ, Cottler LB, Goldberger BA, et al. Trends in characteristics of fentanyl-related poisonings in
 the United States, 2015-2021. *The American journal of drug and alcohol abuse*. 2022:1-10.
 doi:10.1080/00952990.2022.2081923

353

Anker JJ, Carroll ME. Females are more vulnerable to drug abuse than males: evidence from
 preclinical studies and the role of ovarian hormones. *Current topics in behavioral neurosciences*. 2011;8:73-96.
 doi:10.1007/7854_2010_93

Nicolas C, Zlebnik NE, Farokhnia M, Leggio L, Ikemoto S, Shaham Y. Sex Differences in Opioid and
Psychostimulant Craving and Relapse: A Critical Review. *Pharmacological reviews*. 2022;74(1):119-140.
doi:10.1124/pharmrev.121.000367

361

12. Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. *Drug Alcohol Depend*. Jun 11 2004;74(3):265-72.

- 364
- 13. Kosten TA, Gawin FH, Kosten TR, Rounsaville BJ. Gender differences in cocaine use and treatment
 response. *J Subst Abuse Treat*. Jan-Feb 1993;10(1):63-6. doi:0740-5472(93)90100-G [pii]
- 367
- Anglin MD, Hser YI, McGlothlin WH. Sex differences in addict careers. 2. Becoming addicted. *The American journal of drug and alcohol abuse*. 1987;13(1-2):59-71.
- 370
- 15. McCance-Katz EF, Carroll KM, Rounsaville BJ. Gender differences in treatment-seeking cocaine abusers--implications for treatment and prognosis. *Am J Addict*. Fall 1999;8(4):300-11.

373

16. Butelman ER, Chen CY, Conybeare RA, et al. Are trait impulsivity and exposure to cannabis or alcohol associated with the age of trajectory of cocaine use? A gender-specific dimensional analysis in humans with cocaine dependence diagnosis. *Experimental and clinical psychopharmacology*. 2019:10.1037/pha0000314. doi:10.1037/pha0000314

378

Stoltman JJ, Woodcock EA, Lister JJ, Greenwald MK, Lundahl LH. Exploration of the telescoping effect
among not-in-treatment, intensive heroin-using research volunteers. *Drug Alcohol Depend*. Mar 1
2015;148:217-20. doi:10.1016/j.drugalcdep.2015.01.010

382

18. Woodcock EA, Lundahl LH, Stoltman JJ, Greenwald MK. Progression to regular heroin use:
 examination of patterns, predictors, and consequences. *Addictive behaviors*. Jun 2015;45:287-93.
 doi:10.1016/j.addbeh.2015.02.014

386

Butelman ER, Chen CY, Brown KG, Kreek MJ. Escalation of drug use in persons dually diagnosed with
 opioid and cocaine dependence: Gender comparison and dimensional predictors. *Drug Alcohol Depend*. Oct
 22 2019;205:107657. doi:10.1016/j.drugalcdep.2019.107657

390

Lynch A, Arndt S, Acion L. Late- and Typical-Onset Heroin Use Among Older Adults Seeking
 Treatment for Opioid Use Disorder. *The American Journal of Geriatric Psychiatry*. 2021/05/01/ 2021;29(5):417 doi:https://doi.org/10.1016/j.jagp.2020.12.005

394

Hansen JL, Heilig M, Kalso E, et al. Problematic opioid use among osteoarthritis patients with chronic
 post-operative pain after joint replacement: analyses from the BISCUITS study. *Scandinavian journal of pain*.
 Feb 20 2023;doi:10.1515/sjpain-2022-0137

398

Huhn AS, Strain EC, Tompkins DA, Dunn KE. A hidden aspect of the U.S. opioid crisis: Rise in firsttime treatment admissions for older adults with opioid use disorder. *Drug Alcohol Depend*. Dec 1
2018;193:142-147. doi:10.1016/j.drugalcdep.2018.10.002

402 403 404 405	23. Kariisa M, Davis NL, Kumar M, et al. Vital Signs: Drug Overdose Deaths, by Selected Sociodemographic and Social Determinants of Health Characteristics — 25 States and the District of Columbia, 2019–2020. https://www.cdc.gov/mmwr/volumes/71/wr/mm7129e2.htm
406 407 408 409	24. D.E.A. <i>DRUG ENFORCEMENT ADMINISTRATION 2020 NATIONAL DRUG THREAT ASSESSMENT</i> . 2021. https://www.dea.gov/sites/default/files/2021-02/DIR-008- 21%202020%20National%20Drug%20Threat%20Assessment_WEB.pdf
410 411 412	25. Badiani A, Belin D, Epstein D, Calu D, Shaham Y. Opiate versus psychostimulant addiction: the differences do matter. <i>Nature reviews Neuroscience</i> . Oct 5 2011;12(11):685-700. doi:10.1038/nrn3104
413 414 415	26. Baldo BA, Rose MA. Mechanisms of opioid-induced respiratory depression. <i>Archives of Toxicology</i> . 2022/04/26 2022;doi:10.1007/s00204-022-03300-7
416 417 418	27. Liu S, Kim DI, Oh TG, et al. Neural basis of opioid-induced respiratory depression and its rescue. <i>Proc Natl Acad Sci USA</i> . Jun 8 2021:118(23):e2022134118. doi:10.1073/pnas.2022134118
419 420 421	28. Britch SC, Walsh SL. Treatment of opioid overdose: current approaches and recent advances. <i>Psychopharmacology</i> . Apr 7 2022;239:2063-81. doi:10.1007/s00213-022-06125-5
422 423 424 425	29. Kelly E, Sutcliffe K, Cavallo D, Ramos-Gonzalez N, Alhosan N, Henderson G. The anomalous pharmacology of fentanyl. <i>British journal of pharmacology</i> . May 24 2021;doi: 10.1111/bph.15573doi:10.1111/bph.15573
426 427 428 429	30. Torralva PR, Janowsky A. Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis. <i>The Journal of pharmacology and experimental therapeutics</i> . Sep 6 2019;DOI: 10.1124/jpet.119.258566doi:10.1124/jpet.119.258566
430 431 432 433	31. Roy S, Bruehl S, Feng X, et al. Developing a risk stratification tool for predicting opioid-related respiratory depression after non-cardiac surgery: a retrospective study. <i>BMJ open</i> . Sep 5 2022;12(9):e064089. doi:10.1136/bmjopen-2022-064089
434 435 436 437	32. Khanna AK, Bergese SD, Jungquist CR, et al. Prediction of Opioid-Induced Respiratory Depression on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective, Observational Trial. <i>Anesthesia and analgesia</i> . Oct 2020;131(4):1012-1024. doi:10.1213/ane.000000000004788
438 439 440	33. Garrett J, Vanston A, Ogola G, et al. Predicting opioid-induced oversedation in hospitalised patients: a multicentre observational study. <i>BMJ open</i> . Nov 24 2021;11(11):e051663. doi:10.1136/bmjopen-2021-051663
441 442 443 444	34. Dahan A, Sarton E, Teppema L, Olievier C. Sex-related differences in the influence of morphine on ventilatory control in humans. <i>Anesthesiology</i> . Apr 1998;88(4):903-13. doi:10.1097/00000542-199804000-00009

445 446 447	35. Bachi K, Mani V, Jeyachandran D, Fayad ZA, Goldstein RZ, Alia-Klein N. Vascular disease in cocaine addiction. <i>Atherosclerosis</i> . Jul 2017;262:154-162. doi:10.1016/j.atherosclerosis.2017.03.019
448 449 450	36. Jayanthi S, Daiwile AP, Cadet JL. Neurotoxicity of methamphetamine: Main effects and mechanisms. <i>Experimental neurology</i> . 2021/10/01/ 2021;344:113795. doi:https://doi.org/10.1016/j.expneurol.2021.113795
451 452 453 454	37. Lukas SE, Sholar M, Lundahl LH, et al. Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. <i>Psychopharmacology</i> . 1996/06/01 1996;125(4):346-354. doi:10.1007/BF02246017
455 456 457	38. Evans SM, Haney M, Fischman MW, Foltin RW. Limited sex differences in response to "binge" smoked cocaine use in humans. <i>Neuropsychopharmacol</i> . Sep 1999;21(3):445-54. doi:10.1016/s0893-133x(98)00120-1
458 459 460 461	39. Singha AK, McCance-Katz EF, Petrakis I, Kosten TR, Oliveto A. Sex Differences in Self-Reported and Physiological Response to Oral Cocaine and Placebo in Humans. <i>The American journal of drug and alcohol abuse</i> . 2000/01/01 2000;26(4):643-657. doi:10.1081/ADA-100101900
462 463 464	40. Kosten TR, Kosten TA, McDougle CJ, et al. Gender differences in response to intranasal cocaine administration to humans. <i>Biological psychiatry</i> . Jan 15 1996;39(2):147-8. doi:10.1016/0006-3223(95)00386-x
465 466 467 468	41. Luthar SS, Gushing G, Rounsaville BJ. Gender differences among opioid abusers: Pathways to disorder and profiles of psychopathology. <i>Drug Alc Depend</i> . 1996/12/11/ 1996;43(3):179-189. doi:https://doi.org/10.1016/S0376-8716(96)01310-5
469 470 471 472	42. Bagley SM, Gai MJ, Earlywine JJ, Schoenberger SF, Hadland SE, Barocas JA. Incidence and Characteristics of Nonfatal Opioid Overdose Among Youths Aged 11 to 24 Years by Sex. <i>JAMA Netw Open</i> . Dec 1 2020;3(12):e2030201. doi:10.1001/jamanetworkopen.2020.30201
473 474 475 476	43. Norton A, Hayashi K, Johnson C, Choi J, Milloy MJ, Kerr T. Injecting drugs alone during an overdose crisis in Vancouver, Canada. <i>Harm reduction journal</i> . 2022/11/17 2022;19(1):125. doi:10.1186/s12954-022-00701-w
477 478 479	44. Ho JY. Cycles of Gender Convergence and Divergence in Drug Overdose Mortality. <i>Popul Dev Rev</i> . Sep 2020;46(3):443-470. doi:10.1111/padr.12336
480 481 482 483	45. Kaplovitch E, Gomes T, Camacho X, Dhalla IA, Mamdani MM, Juurlink DN. Sex Differences in Dose Escalation and Overdose Death during Chronic Opioid Therapy: A Population-Based Cohort Study. <i>PloS one</i> . 2015;10(8):e0134550. doi:10.1371/journal.pone.0134550
484 485 486 487	46. Serdarevic M, Striley CW, Gurka KK, Leeman RF, Cottler LB. Sex differences in prescription opioid use patterns assessed through a community engagement program in Florida. <i>Drug Alc Depend</i> . 2019/11/01/2019;204:107568. doi:https://doi.org/10.1016/j.drugalcdep.2019.107568

488 47. Hser YI, Anglin MD, McGlothlin W. Sex differences in addict careers. 1. Initiation of use. The American 489 journal of drug and alcohol abuse. 1987;13(1-2):33-57. 490 491 48. Goetz TG, Becker JB, Mazure CM. Women, opioid use and addiction. FASEB journal : official 492 publication of the Federation of American Societies for Experimental Biology. Feb 2021;35(2):e21303. 493 doi:10.1096/fj.202002125R 494 495 Antoine D, Heffernan S, Chaudhry A, King V, Strain EC. Age and gender considerations for technology-49. 496 assisted delivery of therapy for substance use disorder treatment: A patient survey of access to electronic 497 devices. Addictive disorders & their treatment. Dec 2016;15(4):149-156. doi:10.1097/adt.00000000000088 498 499 50. Shover CL, Falasinnu TO, Dwver CL, et al. Steep increases in fentanyl-related mortality west of the 500 Mississippi River: Recent evidence from county and state surveillance. Drug Alcohol Depend. Nov 1 501 2020;216:108314. doi:10.1016/j.drugalcdep.2020.108314 502 503 51. Tabatabai M, Cooper RL, Wilus DM, et al. The Effect of Naloxone Access Laws on Fatal Synthetic 504 505 Opioid Overdose Fatality Rates. J Prim Care Community Health. Jan-Dec 2023;DOI: 10.1177/21501319221147246doi:10.1177/21501319221147246 506 507 52. Kerridge BT, Chou SP, Pickering RP, et al. Changes in the prevalence and correlates of cocaine use 508 and cocaine use disorder in the United States, 2001–2002 and 2012–2013. Addictive behaviors. 2019/03/01/ 509 2019;90:250-257. doi:https://doi.org/10.1016/j.addbeh.2018.11.005 510 511 53. Kerridge BT, Saha TD, Chou SP, et al. Gender and nonmedical prescription opioid use and DSM-5 512 nonmedical prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and 513 Related Conditions - III. Drug Alcohol Depend. Nov 1 2015;156:47-56. doi:10.1016/j.drugalcdep.2015.08.026 514 515 54. Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacology & therapeutics. Oct 9 516 2021:108019. doi:10.1016/j.pharmthera.2021.108019 517 518 55. Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health 519 520 Statistics. Centers for Disease Control. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm 521 56. 522 Clayton JA, Tannenbaum C. Reporting Sex, Gender, or Both in Clinical Research? Jama. 2016;316(18):1863-1864. doi:10.1001/jama.2016.16405 523 524 525 57. Hedegaard H, Miniño AM, Warner M. Co-involvement of opioids in drug overdose deaths involving cocaine and psychostimulants; https://doi.org/10.15620/cdc:103966. 526 527 58. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. 528 Current opinion in psychiatry. Jul 1 2021;34(4):344-350. doi:10.1097/yco.000000000000717 529 530

531 59. Tweed EJ, Miller RG, Schofield J, Barnsdale L, Matheson C. Why are drug-related deaths among women increasing in Scotland? A mixed-methods analysis of possible explanations. Drugs (Abingdon Engl). 532 Jan 2 2022;29(1):62-75. doi:10.1080/09687637.2020.1856786 533 534 60. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who 535 inject drugs: a systematic review and meta-analysis. Bull World Health Organ. Feb 1 2013;91(2):102-23. 536 doi:10.2471/blt.12.108282 537 538 Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am. 61. 539 Sep 2011;38(3):425-40. doi:10.1016/j.ogc.2011.05.002 540 541 62. Dietrich JB. Alteration of blood-brain barrier function by methamphetamine and cocaine. Cell and tissue 542 research. 2009/06/01 2009;336(3):385-392. doi:10.1007/s00441-009-0777-y 543 544 63. Kohno M, Link J, Dennis LE, et al. Neuroinflammation in addiction: A review of neuroimaging studies 545 and potential immunotherapies. Pharmacology Biochemistry and Behavior. 2019/04/01/ 2019;179:34-42. 546 doi:https://doi.org/10.1016/j.pbb.2019.01.007 547 548 S.A.M.H.S.A. Key Substance use and mental health indicators in the United States: Results from the 64. 549 2021 National Survey on Drug Use and Health. 550 https://www.samhsa.gov/data/sites/default/files/reports/rpt39443/2021NSDUHFFRRev010323.pdf 551 552 553 65. Ferreira AI, Martinez LF, Guisande MA. Risky behavior, personality traits and road accidents among university students. European Journal of Education and Psychology. 2009;2:79-98. doi:10.30552/ejep.v2i2.23 554 555 66. IIHS. Fatality Facts 2020: Males and females. 2023. https://www.iihs.org/topics/fatality-556 statistics/detail/males-and-females#yearly-snapshot 557 558 67. Daiwile AP. Javanthi S. Cadet JL. Sex differences in methamphetamine use disorder perused from pre-559 clinical and clinical studies: Potential therapeutic impacts. Neuroscience and biobehavioral reviews. Jun 560 2022;137:104674. doi:10.1016/j.neubiorev.2022.104674 561 562 68. O'Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J. Trends in and Characteristics of Drug 563 Overdose Deaths Involving Illicitly Manufactured Fentanyls — United States, 2019–2020 564 https://www.cdc.gov/mmwr/volumes/70/wr/mm7050e3.htm 565 566 69. Shai D. Problems of accuracy in official statistics on drug-related deaths. Article. International Journal 567 568 of the Addictions. 1994;29(14):1801-1811. 569 Thompson K, Barocas JA, Delcher C, et al. The prevalence of opioid use disorder in Kentucky's 570 70. counties: A two-year multi-sample capture-recapture analysis. Drug Alc Depend. 2023/01/01/ 571 2023;242:109710. doi:https://doi.org/10.1016/j.drugalcdep.2022.109710 572

574 Figure Legends

576	Figure 1: Upper panel: Past-year misuse of any opioid (upper panel) in males and females, all ages combined.
577	Lower panels: Overdose mortality due to synthetic opioids and heroin in males and females; all ages
578	combined. For all panels, each symbol (open circles) is one jurisdiction. Note different axis ranges in the
579	panels. Spearman correlations for males and females in each jurisdiction are included. The red line indicates
580	the best-fit simple linear regression (not shown in the upper panel, as the 95%CI of the slope overlapped with
581	0). The dashed black line indicates identity.
582	
583	Figure 2: Upper panels: Past-year misuse of psychostimulants and cocaine in males and females, all ages
584	combined. Lower panels: Overdose, mortality due to synthetic opioids and heroin in males and females; all
585	ages combined. For all panels, each symbol (open circles) is one jurisdiction. Note different axis ranges in the
586	panels. Spearman correlations for males and females in each jurisdiction are included. The red line indicates
587	the best-fit simple linear regression. The dashed black line indicates identity.
588	
589	Figure 3: Male/Female ratios for past-year misuse of relevant substances and for overdose mortality (shown in
590	logarithmic axis). Data were analyzed with Wilcoxon's tests, followed by Bonferroni analysis where appropriate
591	(i.e., based on opioid misuse data being used both in synthetic opioid and heroin panels). P-values are shown
592	as **** (p=0.0001) and *** (p=0.001). Jurisdictions with missing data were excluded from the analysis.

597	Figure 4: Overdose mortality in males and females, for consecutive 10-year age bins. Note the different Y-axis
598	ranges in the different panels. Means and 95%CI are calculated across 51 jurisdictions. Log –transformed
599	overdose data were analyzed with univariate mixed-effects effects ANOVAs (sex x age bin). Bonferroni post-
600	hoc tests for sex at each age bin are shown with black brackets (* is p<0.05; **** is p<0.0001). The label "excl."
601	indicates that the age bin was excluded from ANOVA analysis due to insufficient available data (see Methods
602	and eTable 2). Full ANOVA table is present in the Supplement (eTable 3)

Figure 5: β(beta)-parameter for sex as a factor in overdose mortality, from multiple linear regressions. The
outcome was log-transformed overdose mortality per 100,000 population. The data were adjusted for
jurisdiction-specific levels of misuse in males and females, and for three demographic variables (%White,
%African American, and household assets). Full regression data are presented in the Supplement (eTable 4,
eTable 5).

Figure 1: Opioid misuse and overdose mortality







Female (crude death rate/100K)





Figure 4. Summary of overdose death rates for different drug categories across the lifespan



Figure 5: Sex as a factor in overdose mortality after adjustment for levels of drug misuse and demographic variables

Synthetic opioid overdose mortality



All ages (15-74) 15-24 insufficient data 25-34 Separate 35-44 Age bins 45-54 55-64 65-74 insufficient data -0.5 0.0 0.5 1.0 1.5 **β-parameter for sex** (males; females as reference group)

Psychostimulant overdose mortality





Cocaine overdose mortality

Heroin Overdose Mortality